Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2021 08:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
June 07, 2021 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

– CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to First- and Third-generation EGFR Inhibitors – – CFT8919 Demonstrates Intracranial Activity Pre-clinically, Indicating the...
May 26, 2021 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies

– IND Submission for CFT8919 Anticipated mid-2022; Phase 1/2 Trial Initiation Expected by YE 2022 – – CFT8919 is Potent and Mutant-Selective BiDACTM Degrader of EGFR L858R for the Treatment of...
May 20, 2021 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Lauren White as Chief Financial Officer

WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy...
May 13, 2021 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

– Preclinical Data for CFT7455, a novel IKZF1/3 Degrader, in Non-Hodgkin's Lymphoma Xenograft Models Accepted for Presentation at the International Conference on Malignant Lymphoma (ICML) in June – –...
May 12, 2021 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy...
April 10, 2021 15:05 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021

– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models – –...
March 11, 2021 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results

– Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of...
March 10, 2021 16:41 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting

WATERTOWN, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively...
February 24, 2021 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively...